AI Terminal
ARECOR THERAPEUTICS PLC
Report Publication Announcement • Aug 10, 2023
7494_rns_2023-08-10_a37cc261-e46d-43f1-be21-fa1e04d225cb.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 8550I
Arecor Therapeutics PLC
10 August 2023
Arecor Therapeutics plc
("Arecor" or the "Group")
NOTICE OF INTERIM RESULTS
Cambridge, UK, 10 August 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, will announce its Interim Results for the six months ended 30 June 2023 on Thursday 14 September 2023.
Sarah Howell, Chief Executive Officer, and Susan Lowther, Chief Financial Officer, will host an in-person briefing for analysts at 11:00am BST on the day of the results at the offices of Panmure Gordon, 40 Gracechurch St, London, EC3V 0BT. There will also be a live webcast and conference call with a Q&A session.
For more details or to attend the briefing, please contact [email protected]
-ENDS-
For more information, please contact:
| Arecor Therapeutics plc | www.arecor.com |
| Dr Sarah Howell, Chief Executive Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| Susan Lowther, Chief Financial Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| Mo Noonan, Communications | Tel: +44 (0) 7876 444977 Email: [email protected] |
| Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500 |
| Consilium Strategic Communications | |
| Chris Gardner, David Daley, Lindsey Neville | Tel: +44 (0) 20 3709 5700 Email: [email protected] |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORQKLFBXVLZBBK